1. Vimentin and Ki-67 immunolabeling in canine gastric carcinomas and their prognostic value
- Author
-
Ana R. Flores, Alexandra Rêma, João R. Mesquita, Marian Taulescu, Fernanda Seixas, Fátima Gärtner, and Irina Amorim
- Subjects
Dogs ,Ki-67 Antigen ,General Veterinary ,Stomach Neoplasms ,Carcinoma ,Animals ,Vimentin ,Dog Diseases ,Prognosis - Abstract
This study evaluated the expression of vimentin and Ki-67 proliferative index (PI) by immunohistochemistry in 30 canine gastric carcinomas (GCs) and a possible association with clinical and pathological features and patient’s survival time. Vimentin immunoreactivity was assessed in neoplastic cells (in primary lesions, emboli, and metastases) and tumor-associated stroma (TAS) of canine GCs. Ki-67 PI was quantified in the neoplastic epithelial component. Vimentin immunolabeling in neoplastic cells was found in 30% of the primary lesions, in 82% of the neoplastic emboli, and in 50% of the metastases; in TAS, it was observed in all cases. A mean of 16% of the TAS was immunolabeled for vimentin. High vimentin immunolabeling in the TAS (>16%) was detected in 40% of cases. The average value of Ki-67 PI was 50%, and 80% of the lesions had Ki-67 PI above 20%. Vimentin immunolabeling in neoplastic cells was more frequent in less-differentiated carcinomas (diffuse [29%] and indeterminate types [75%]) than well-differentiated carcinomas (intestinal type [0%], P = .049). No significant differences were observed in vimentin immunolabeling in the TAS or Ki-67 PI according to histological diagnosis, depth of invasion, presence of neoplastic emboli or metastases. However, vimentin immunolabeling in the TAS was positively correlated with Ki-67 PI ( r = .394, P = .031). Furthermore, a moderate negative correlation was observed between Ki-67 PI and survival time ( r = −0.540). Our results suggest that vimentin and Ki-67 PI have potential for providing prognostic information in cases of canine GCs.
- Published
- 2022